Search
Hydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigationalHydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. … [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsSynonyms: N-Hydroxyurea, N-CarbamoylhydroxylamineMaprotiline
go.drugbank.com/drugs/DB00934ApprovedMaprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). … It differs from TCAs in that it does not appear to block serotonin reuptake.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: LUDIOMIL 75 MG TABLET, 14 ADET, MAPROTIL 75 MG TABLET, 14 ADETLanthanum carbonate
go.drugbank.com/drugs/DB06792ApprovedLanthanum carbonate is a phosphate binder marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. … It is a large pill that requires thorough chewing to avoid choking and other gastrointestinal adverse effects.
Synonyms: Lanthanum(3+) carbonateProducts: FOSRENOL 500 MG, FOSRENOL 750 MG.Carbidopa
go.drugbank.com/drugs/DB00190ApprovedInvestigationalCarbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. … An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.
Mixtures: LEVO/CA/EN 100/25/200 STD, LEVO/CA/EN 150/37.5/200STDCategories: Aromatic L-amino Acid Decarboxylase InhibitorsCabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigationalCabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. … [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: CABOMETYX 40 MG FİLM KAPLI TABLET, 30 ADET, CABOMETYX 20 MG FİLM KAPLI TABLET, 30 ADETConjugated estrogens
go.drugbank.com/drugs/DB00286ApprovedInvestigationalIt also presents a large number of unidentified molecules with weak estrogenic activity as well as non-human molecules when it is obtained from pregnant mares urine. … sulfate, 3% of equilenin sulfate, 5% of 17-alpha and 17-beta-dihydroequilenin sulfate, 2% of 17-alpha-estradiolsulfate and 3% of 17-beta-estradiolsulfate.
Mixtures: DUAVIVE 20 mg/0.45 mg modified - release tablets, DUAVİVE 0.45 MG/20 MG DEĞİŞTİRİLMİŞ SALIMLI TABLET, 30 TABLETCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesZinc citrate
go.drugbank.com/drugs/DB11154ApprovedInvestigationalZinc citrate is a zinc salt of citric acid. It is available as dietary supplements as a treatment of zinc deficiency and source of zinc, which is an essential trace element.
Mixtures: Vitamin A C E W.niacinam.beta Car.and Min., Collag-ENProducts: Zinc 50 mgCardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))
smpdb.ca/view/SMP0029705MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/18:4(6Z,9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))
smpdb.ca/view/SMP0220117MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.